title: 16-year experience at M. D. Anderson Cancer Center with primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large cell lymphoma.
abstract: One hundred and seven adult cases of untreated diffuse large cell lymphoma (DLCL) were retrospectively analyzed for primary CD30 antigen expression, anaplastic morphology, and long-term prognosis. Tissue samples from 36 patients stained strongly for CD30, and of these, 22 showed anaplastic morphology. Patients with CD30-positive DLCL presented more frequently with skin involvement, constitutional symptoms, more advanced Ann Arbor stage disease, and at a younger age when compared to patients with CD30-negative DLCL. Both groups had a similar complete response rate (78%). Patients with CD30-positive DLCL had a favorable survival rate when compared to patients with CD30-negative DLCL, although the difference was not statistically significant (73% vs. 55%, p = 0.28). Among the CD30-positive DLCL patients, those with anaplastic morphology presented more frequently with extranodal disease and T-cell phenotype when compared to patients with non-anaplastic morphology, but both groups had similar rates of complete response and long-term survival. All 107 patients were treated initially with a doxorubicin-containing chemotherapy regimen. These findings suggest a favorable outlook for adult patients with DLCL that has primary CD30 antigen expression regardless of the presence or absence of anaplastic morphology. Which support our previous observations.
authors: Department of Hematology, University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA.
authors: J E
authors: JE
authors: Romaguera
authors: J
authors: J
authors: Garcia-Foncillas
authors: F
authors: F
authors: Cabanillas
mesh_terms: D005500:Follow-Up Studies; D015870:Gene Expression; D006801:Humans; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D017730:Ki-1 Antigen / Q000032:analysis* / Q000096:biosynthesis; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology* / Q000401:mortality / Q000473:pathology*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000276:immunology* / Q000401:mortality / Q000473:pathology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D012867:Skin / Q000473:pathology; D015996:Survival Rate; D013781:Texas; D013997:Time Factors
chemical_list: D017730:Ki-1 Antigen